Popular breast cancer drugs don’t work the way we thought they did
Some of the most commonly used drugs for treating hereditary breast and ovarian cancers may…
Browsing: PARP inhibitors
Researchers discover drug resistance mechanism in leukemia, ID treatment strategy
Like packaging designed to create a protective environment around a product, the mix of cells…
Why some cancers may respond poorly to key drugs discovered
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that…
Immune system could be trained to spot drug-resistant cancers
Aggressive cancers could be treated with immunotherapies that direct the immune system to kill cancer…
Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma
A type of drug known as a PARP inhibitor, already used to treat breast and…
Tailoring an anti-cancer drug for optimal tumour cell killing
In a study published this in Science, Université de Montreal, Canada, researchers report key structural and…
Decoding cancer’s molecular signature
Medications known as PARP inhibitors have emerged as a promising therapy for several forms of…
AACR 2019: PARP inhibitors can shrink tumours in pancreatic cancer patients with specific mutations
Switching pancreatic cancer patients to the PARP inhibitor rucaparib as maintenance therapy instead of continuing…
A new toolkit for studying how ‘PARP’ activity boosts cancers
A new method developed by scientists at Johns Hopkins Bloomberg School of Public Health is…
Discovery paves way for improved ovarian cancer care
Melbourne scientists have revealed a better way to identify which patients should respond to PARP…